Analyzing immune responses to COVID-2019 vaccination using single-cell techniques
Official title: Evolution of Immune System in Healthy Adults After Vaccination of New Coronavirus (COVID-2019) Inactivated Vaccine Based on Single Cell Multi-Omics Technologies
Run by RenJi Hospital · NCT04871932 · Data updated 2026-11-12
This study is testing how healthy adults' immune systems respond to the COVID-19 vaccine using advanced techniques to better understand the different types of immune cells involved.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | February 1, 2021 |
| Main results expected | November 3, 2026 |
| Study ends | December 3, 2026 |
| Registry record updated | June 3, 2021 |
| Trial ID | NCT04871932 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy adults aged 18 to 50 with no significant medical history or current infections.
✕Probably not a fit
Patients with infectious diseases, autoimmune disorders, or a history of major health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to recruit healthy adults aged 18 to 50 to analyze the immune response to COVID-2019 vaccination through advanced single-cell multi-omics techniques. By utilizing single-cell RNA sequencing, the study will classify peripheral blood mononuclear cells (PBMCs) to gain insights into immune cell heterogeneity and functionality. The research focuses on understanding the variations in immune cell populations and their potential implications for disease-related research. The findings could enhance our understanding of the immune system's response to vaccination.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the immune response to COVID-2019 vaccination, potentially leading to improved vaccine strategies.
How similar studies have gone: Other studies utilizing single-cell sequencing have shown promise in understanding immune responses, indicating that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Age from 18 to 50 years; 2. No history of major diseases, no history of bacterial or viral infection in the past 3 months; 3. No recent history of surgery or trauma; 4 No history of smoking or alcoholism; 5. No immune system disease. Exclusion Criteria: 1\. Infectious diseases; 2. Tumor diseases; 3. Hematological diseases; 4. History of hypertension and diabetes; 5 Autoimmune diseases; 6 History of liver and kidney insufficiency; 7. History of previous cardiovascular diseases; 8. Pregnancy Or breast-feeding; 9. Past and current use of immunosuppressive drugs
Where it's running
-
Cardiology, Ren Ji Hospital
Shanghai, China Recruiting
Study contacts
- Principal investigator: Jun Pu, MD,PhD — Cardiology, Ren Ji Hospital Shanghai, China
- Study coordinator: Jun Pu, MD,PhD
- Email: pujun310@hotmail.com
- Phone: 86-21-68383477
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tracking how labeled glucose is used by immune cells in real time
Adults will receive a short infusion of safe, non-radioactive labeled glucose while researchers take blood immune cells to see how those cells use glucose for energy and as building material.
-
Exploring how playing in sand affects atopic dermatitis in children
This study is testing if playing in sand can help young children with eczema feel better by looking at their skin and immune system changes.
-
Exploring arginine supplementation for immune response in postoperative infants
This study is testing if giving arginine supplements can help improve the immune response in infants who have had major bowel surgery or have a serious gut condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.